美索巴莫

用途

• Relief of moderate conditions
• Controlling severe effects of strychnine and tetanus
• General muscle relaxation (Tablets)
• Adjunctive treatment (control of seizures/muscle tremors) of permethrin toxicity
• General muscle spasms, tetanus, toxicities
• Moderate conditions
• Severe conditions
• General muscle relaxation
• Oral administration
• Acute rhabdomyolysis
• Treatment of CNS hyperactivity
• Relief of moderate conditions
• Controlling severe effects of strychnine and tetanus

給藥方式

可能的副作用

• Sedation
• Salivation
• Emesis
• Lethargy
• Weakness
• Ataxia

注意事項與禁忌

• Food-producing animals
• Renal disease (injectable formulation only, due to PEG 300 vehicle)
• Known hypersensitivity to methocarbamol
• Subcutaneous (SC) administration
• No specific contraindications available, but use with caution in renal or hepatic impairment.
• **Administration Warnings:** * **Intravenous Use:** Give IV slowly. Do not exceed a rate of **2 mL/minute** in dogs and cats. Avoid extravasation as it can cause tissue irritation. * **Do NOT administer subcutaneously (SC).** **Organ System Warnings:** * **Renal Impairment:** The injectable product contains polyethylene glycol (PEG) 300, which can increase pre-existing acidosis and urea retention. Avoid IV use in patients with known or suspected renal pathology. * **Working Animals:** May impair the abilities of working animals due to CNS depressant effects. **Reproductive/Nursing:** * FDA Category C for pregnancy. Use with caution as a last resort when benefits clearly outweigh risks. Safety during lactation is unknown, though considered compatible with breastfeeding in humans. **Laboratory Considerations:** * May falsely elevate urinary values of vanillylmandelic acid (VMA) or 5-HIAA.

藥物相互作用

• CNS Depressants (e.g., opioids, benzodiazepines, barbiturates): Additive CNS depression may occur when given concurrently.
• Pyridostigmine: May cause severe weakness (reported in a human patient with myasthenia gravis).
• Other CNS depressants: Additive CNS depression

常見問題